Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsAjantapharma

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Go long in Cadila Health, Axis Bank, Allahabad Bank: Gaba

      Prakash Gaba of prakashgaba.com recommends going long in Cadila Healthcare and Axis Bank and Allahabad Bank.

    • Buy Ajanta Pharma, Havells India, Tata Elxsi: Ashish Kyal

      Ashish Kyal of wavesstrategy.com recommends buying Ajanta Pharma, Havells India and Tata Elxsi.

    • Buy Ajanta Pharma on dips, sell PSU banks: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Ajanta Pharma on dips.

    • Like Ajanta Pharma, HUL may test Rs 815-820: Prakash Gaba

      Prakash Gaba of prakashgaba.com likes Ajanta Pharma and feels that Hindustan Unilever may move up and test Rs 815-820.

    • Here are Manoj Murlidharan‘s top F&O picks

      In an interview to CNBC-TV18's Latha Venkatesh and Sonia Shenoy, Manoj Murlidharan of Religare Securities and Yogesh Radke of Edelweiss Securities gave their outlook on Futures and Options (F&O) side of the market, specific stocks and sectors.

    • Buy Ajanta Pharma, ITC, Power Grid; sell Marico: Prakash Gaba

      Prakash Gaba of prakashgaba.com is of the view that one can buy Ajanta Pharma, ITC and Power Grid and advises selling Marico.

    • Buy Sun Pharma; sell Tata Motors, IFCI: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Sun Pharma and Apollo Hospitals and advises selling Tata Motors and IFCI.

    • Buy SKS Micro, Cadila Health; sell Ajanta Pharma: Gaurav Bissa

      Gaurav Bissa of LKP Securities recommends buying SKS Microfinance and Cadila Healthcare and advises selling Ajanta Pharma.

    • Buy Jubilant Foodworks; CESC may test Rs 840: Prakash Gaba

      Prakash Gaba of prakashgaba.com is of the view that one may buy Jubilant Foodworks.

    • Buy Ajanta Pharma; sell Tech Mahindra: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com advises buying Ajanta Pharma and suggests selling Tech Mahindra.

    • Sell Reliance Ind, DLF; buy Cipla: Rahul Mohindar

      Rahul Mohindar of viratechindia.com recommends shorting Reliance Industries and buying Cipla while he feels that Ajanta Pharma may test Rs 1100.

    • Upbeat on Glenmark, Wockhardt, Ajanta Pharma: Sukhani

      Sudarshan Sukhani of s2analytics.com is upbeat on Glenmark Pharma, Wockhardt and Ajanta Pharma.

    • Bull's Eye: Buy BoI, SAIL, Jet Airways, Kaveri Seed, Gati

      Rakesh Bansal of VP, RK Global advises buying Tata Motors DVR with a target of Rs 311.

    • Invest in Alembic Pharma, says Dipan Mehta

      Dipan Mehta, Member at BSE & NSE is of the view that one can invest in Alembic Pharma.

    • Buy Ajanta Pharma, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Ajanta Pharma.

    • Buy Ajanta Pharma, target Rs 1700: Sahil Kapoor

      Sahil Kapoor, AVP-Retail Capital Markets at Edelweiss Financial Services recommends buying Ajanta Pharma for a target of Rs 1700.

    • Bull's Eye: Buy Dish TV, NIIT, UPL, Maruti, PVR, IRB Infra

      Meghana V Malkan of malkansview.com recommends buying Dish TV India with a stoploss at Rs 103 and target of Rs 114 and NIIT with a stoploss at Rs 92 and target of Rs 110.

    • Buy Ajanta Pharma, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Ajanta Pharma from the pharma space.

    • Bull's Eye: Buy Mindtree, Thomas Cook, Praj Ind, DLF, Ceat

      Rakesh Bansal of RK Global recommends buying Ceat with a target of Rs 1325 and DLF with a target of Rs 140.

    • 6 stock ideas to liven up your trade

      Meghana V Malkan of malkansview.com is of the view that one may buy Ajanta Pharma with a target of Rs 1555.

    • Bull's Eye: Buy HDIL, PFC, Bata, sell UPL, Hind Zinc, SKS

      Vishal Malkan of malkansview.com is of the view that one may buy Dish TV India with a target of Rs 112.

    • Alembic, Marico qualify as today‘s A-list stocks

      CNBC-TV18's research team brings you the cherry-picked companies from among thousands of listed stocks, which stand out on their own fundamentals. Two worthy of an A-list stature are Alembic Pharma and Marico.

    • Supreme Ind, Ajanta Pharma stock valuations outclass peers

      CNBC-TV18's research team has come out with its A-list. Two companies that emerged winners--Supreme Industries and Ajanta Pharma-- are backed by solid fundamentals like low debt, high cash on books. Here is how they out do their peers.

    • Sell Reliance Infra, Vedanta, Ajanta Pharma: Vishal Malkan

      Vishal Malkan of malkansview.com recommends selling Reliance Infrastructure, Vedanta and Ajanta Pharma.

    • Super Six short term picks for September 2

      Gaurav Bissa of LKP Securities is of the view that one may sell Bank of Baroda with a target of Rs 164.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347